Home

JONATHAN S LEFF

CIK 1215242 · last filed 2026-05-20

JONATHAN S LEFF is a corporate insider who has filed 73 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for LRMR, was dated May 20, 2026. Across all open-market trades the lifetime net is +$72.3M, making them a net buyer over the disclosed history. 30 SEC filings were submitted jointly with INTERMUNE INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

12

Total Filings

73

Lifetime Open-Market Net

$72.28M

Filer Profile

Reported Address
C/O DEERFIELD MANAGEMENT COMPANY, L.P
780 THIRD AVENUE, 37TH FLOOR
NEW YORK, NY 10017
Related Filers
INTERMUNE INC — 30 joint filings, latest 2013-03-01
Nishan M DeSilva — 1 joint filings, latest 2010-06-16
Andrew Ferrer — 1 joint filings, latest 2010-06-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LRMR Director — $3.92 — $0 7 2026-05-20
PHGE Director — $1.85 — $0 2 2025-04-21
BiomX Inc. (PHGE.U) Delisted Director — $0.90 — $0 1 2024-07-15
PRTO Director — $27.78 — $0 2 2018-06-12
AveXis, Inc. (AVXS) Delisted Director — — — $0 1 2016-02-12
ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted Director — — — $0 2 2015-09-15
ALLOS THERAPEUTICS INC (ALTH) Delisted Director 26,124,430 — — $19.74M 8 2012-09-05
INSPIRE PHARMACEUTICALS INC (ISPH) Delisted Director 0 — — $40.00M 6 2011-05-16
ZYMOGENETICS INC (ZGEN) Delisted Director 0 $12.01 $0 $9.54M 13 2010-10-12
NEUROGEN CORP (NRGN) Delisted Director 13,571,411 — — $0 10 2008-07-28
Altus Pharmaceuticals Inc. (ALTU) Delisted Director — $10.12 — $0 3 2008-06-13
Viracta Therapeutics, Inc. (SNSS) Delisted Director 204,956 $18.62 $3.82M $3.00M 3 2008-06-05

Recent Filings

73 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-20 LRMR Grant (A) — $0 EDGAR
2025-05-14 LRMR Grant (A) — $0 EDGAR
2025-04-21 PHGE Grant (A) — $0 EDGAR
2025-04-18 PHGE Grant (A) — $0 EDGAR
2024-07-15 BiomX Inc. (PHGE.U) Delisted Grant (A) — $0 EDGAR
2024-05-31 LRMR Grant (A) — $0 EDGAR
2023-05-11 LRMR Grant (A) — $0 EDGAR
2022-05-12 LRMR Grant (A) — $0 EDGAR
2021-05-17 LRMR Grant (A) — $0 EDGAR
2020-09-30 LRMR Grant (A) — $0 EDGAR
Showing 1–10 of 73
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.